drugset / Trial / NCT07493330
Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).
Timeline
- Start
- 2026-03-23
- Primary completion
- 2029-12-12
- Completion
- 2030-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | Subcutaneous |
| Subject | Decitabine | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Golidocitinib | Small molecule | 150 mg | Oral |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |
| Subject | Zeprumetostat | Small molecule | 350 mg | Oral |